David joined Nura Bio as Senior Vice President, Development Sciences in November 2021. Over the past three decades, he has worked in early drug development functions of large pharma and biotech companies. After starting his career at the preclinical pharmacokinetics group at Sandoz Pharmaceuticals, David joined Amgen as one of the initial pharmacokinetics scientists there. Later he headed up the pharmacokinetics and drug metabolism department of Amgen, in support of small molecule drug discovery and development efforts. He was also the West Coast Site Head for the Global Preclinical Development at Johnson and Johnson, and later served as the Vice President of Preclinical Safety Assessment at Rigel Pharmaceuticals. Prior to joining Nura, David was Senior Vice President of NCE Development at Foresee Pharmaceuticals, a Taiwanese-based biotechnology company. David’s passion is to enable lead optimization of drug candidates, bring the molecules through preclinical and early clinical development, and provide translation information for proof-of-concept studies in patients. He received his Ph.D. in Pharmaceutical Chemistry at the University of California at San Francisco, with his research work focused in the areas of pharmacokinetics, pharmacodynamics, and drug metabolism.